Aquestive Therapeutics, Inc. (AQST) Financials
AQST Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 57.4 million | 163.9 million |
2023-09-30 | 59.4 million | 162.4 million |
2023-06-30 | 57.0 million | 163.6 million |
2023-03-31 | 61.3 million | 170.5 million |
AQST Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -5.0 million | 940000 |
2023-09-30 | -2.5 million | 774000 |
2023-06-30 | -8.7 million | 631000 |
2023-03-31 | 8.8 million | 344000 |
AQST Net Income
No data available :(
AQST Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 23.9 million | - | 5.8 million |
2023-09-30 | 24.9 million | - | 5.9 million |
2023-06-30 | 22.4 million | 20.8 million | 6.0 million |
2023-03-31 | 26.9 million | 25.2 million | 6.0 million |
AQST Shares Outstanding
AQST Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 16000 | 2.9 million | 9.6 million | - |
2023-09-30 | 151000 | 3.2 million | 7.4 million | - |
2023-06-30 | 826000 | 3.5 million | 7.4 million | - |
2023-03-31 | 2000 | 3.5 million | 7.5 million | - |
AQST Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 13.2 million | 4.7 million |
2023-09-30 | 13.0 million | 4.8 million |
2023-06-30 | 13.2 million | 6.6 million |
2023-03-31 | 11.1 million | 4.7 million |
AQST
Price: $3.50
52 week price:
Earnings Per Share: -0.13 USD
P/E Ratio: -11.95
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 208846
Market Capitalization: 351.8 million